Genome-Wide Identification of a Novel Eight-lncRNA Signature to Improve Prognostic Prediction in Head and Neck Squamous Cell Carcinoma

Bowen Yang(Guangzhou University of Chinese Medicine), Zhi Li(Central Hospital Affiliated to Shenyang Medical College), Xiaofang Che(First Hospital of China Medical University), Ying Chen(Sun Yat-sen University), Lu Xu(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Xiujuan Qu(First Hospital of China Medical University), Jiming Shen(First Hospital of China Medical University), Yuee Teng(First Hospital of China Medical University)
Frontiers in Oncology
September 18, 2019
10.3389/fonc.2019.00898
Cited by 43

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417